Pharma BD Deal Intelligence
FierceBiotech framed the $5.9B price tag as 'a defensive rare disease deal' protecting Shire's existing CINRYZE/FIRAZYR HAE franchise from being eroded by…
BioSpace headline declared 'Shire's $6.5B Dyax Bet Pays Off' after Phase 3 success, capturing analyst sentiment that the headline-plus-CVR economics had been…
Following August 2018 FDA approval of Takhzyro, BioPharma Dive cited GlobalData analyst Thomas Moore identifying lanadelumab as the single most valuable asset…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Shire completed acquisition of Dyax Corp. for $37.30/share cash, ~$5.9B total. Adds Phase 3 anti-kallikrein antibody DX-2930 (later lanadelumab/Takhzyro) for HAE prophylaxis to Shire's rare-disease portfolio, complementing FIRAZYR and CINRYZE. Up to $646M contingent value rights tied to FDA approval. Originally announced November 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Dyax Corp. (this deal) | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
| Shire plc / Movetis NV | 2010 | $565M | 37 |
← Browse all deals · How we score deals
More: 2016 deals · Shire plc deals · Rare Disease deals